In most of our PDR models, the determinants of transcriptional heterogeneity seemed to be predominantly related to proliferation, estrogen response and mTOR/metabolic pathways/MYC targets, all pathways that have been previously associated to CDK4/6i resistance14,17,25,30–33 suggesting that different mechanisms might coexist in the same tumor. This evidence concerns the gene MTOR and neoplasm.